Conference
OCELOT - Osimertinib then Chemotherapy in EGFR plus Lung Cancer with Osi Third-line Rechallenge and Osimertinib for Uncommon EGFRm in 1L
Authors
Breadner D; Liu G; Rothenstein J; Wheatley-Price P; Bains P; Cheng S; Wang Y; Sun S; Mithoowani H; Juergens R
Volume
17
Pagination
pp. S412-S413
Publisher
ELSEVIER SCIENCE INC
Publication Date
September 1, 2022
Conference proceedings
JOURNAL OF THORACIC ONCOLOGY
Issue
9
ISSN
1556-0864